Nulojix (belatacept) / BMS - LARVOL DELTA

Belatacept-based immunosuppression in heart transplant recipients: A single center experience. (PubMed, JHLT Open) - "Recipients treated with belatacept-based regimen exhibited a trend of reduced de novo DSA development compared to standard tacrolimus-based regimen controls. Larger studies are needed to evaluate the benefit of belatacept use in heart transplant populations."

Journal • Antibody-mediated Rejection • Cytomegalovirus Infection • Transplantation

VIRABEL: Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept. (clinicaltrials.gov) - P=N/A | N=28 | Recruiting | Sponsor: University Hospital, Rouen | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Transplantation

Potential Benefits of Adding Low-dose Tacrolimus to a Belatacept-based Regimen After Kidney Transplantation. (PubMed, Transplantation) - No abstract available

Journal • Transplantation

CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting. (PubMed, Bioorg Med Chem Lett) - "Key therapeutic approaches include CTLA-4-Ig fusion proteins (abatacept, belatacept) for autoimmune diseases, ICOS agonists (feladilimab, vopratelimab) to enhance anti-tumor immunity, and bispecific CD28-engaging antibodies (CD28xCD3, CD28xPSMA) for cancer immunotherapy. By integrating structural insights with translational drug development, this review provides a framework for optimizing CD28- and ICOS-targeted therapies. Further advancements in biologics, peptide-based inhibitors, and immune checkpoint modulation will enhance the precision and efficacy of immunotherapeutic strategies."

Journal • Review • Immunology • Oncology • CTLA4 • ICOS

Thrombotic Microangiopathy After Kidney Pancreas Transplant Managed With Eculizumab and a Calcineurin Inhibitor-free Basiliximab/Belatacept Maintenance Regimen: Between a Rock and a Hard Place. (PubMed, Transplant Direct) - No abstract available

Journal • Transplantation

Evaluation of Optimal Engraftment Sites for Human Stem Cell-Derived Islets in a Non-Human Primate Model (IPITA 2025) - "The immunosuppressive regimen consists of Thymo, Rituxan, and Enbrel for induction, with maintenance involving Belatacept, anti-CD40L, Rapamycin, and FK506. A notable initial graft loss was observed, as anticipated for primary islet transplantation, ranging from 60% to 98% among transplant sites. This study marks the first report of utilizing a single batch of SC-islets and simultaneously transplanting SC-islets into six sites of one recipient, aiming to eliminate batch and recipient variations. The omentum, a top-performing site, offers high initial graft survival and many advantages over the current favored intrahepatic approach, particularly graft retrievability in teratoma or tumor cases."

Preclinical • Oncology • CD40LG

Belatacept in Pancreas Transplant Patients with Declining Renal Function (IPITA 2025) - "Immunosuppression included rATG induction and tacrolimus/sirolimus based maintenance... Belatacept used to spare or replace CNIs after PTx is safe and can provide some renal recovery. Belatacept was initiated with GFR approaching 20. Earlier introduction may result in better outcomes."

Clinical • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Infectious Disease • Mood Disorders • Myocardial Infarction • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Sarcoma • Solid Tumor • Transplant Rejection • Transplantation

A phase I/IIa trial of regulatory T cell therapy together with donor bone marrow infusion in HLA-mismatched kidney transplantation. (ERA 2025) - "In vitro expanded polyclonal recipient Tregs and MNC-separated donor bone marrow cells are administered within 3 days after transplant; tocilizumab is injected s.c. for the first 3 weeks...Immunosuppression (IS) consists of thymoglobulin; belatacept; sirolimus and steroids... Combined Treg therapy and bone marrow transplantation is safe and feasible in living donor kidney transplantation and induces low-level chimerism which is sufficient to cause clonal deletion of donor specific T cells. These data provide insight into the immunomodulatory effect of combination cell therapy; which allowed for a safe minimization of immunosuppression."

Late-breaking abstract • P1/2 data • Bone Marrow Transplantation • Transplantation

Safety of Continued Belatacept Treatment After Kidney Graft Rejection (ERA 2025) - "We found no evidence of harm in the continued use of belatacept-based immunosuppressive therapy after kidney graft rejection."

Clinical • Antibody-mediated Rejection • Cardiovascular • Hypertension • Nephrology • Transplant Rejection

Reduction in Belatacept Dosing Frequency to Every 2 Months for Kidney Transplant Patients at High Risk of Infections. (PubMed, Clin Transplant) - No abstract available

Journal • Infectious Disease • Transplantation

Crystalline Nephropathy Due to 2,8-Dihydroxyadeninuria in a Transplanted Kidney: 2 Case Reports. (PubMed, Am J Case Rep) - "Management included xanthine oxidase inhibitors, a low-purine diet, and modification of the immunosuppressive regimen with belatacept to reduce long-term tubulointerstitial injury...CONCLUSIONS This case report underscores the importance of early recognition of APRT deficiency through timely biopsy, crystal identification, and genetic testing to guide effective treatment and prevent irreversible damage. It highlights the need for heightened clinical suspicion and tailored post-transplant management strategies in patients with recurrent DHA nephropathy."

Journal • Chronic Kidney Disease • Nephrology • Renal Calculi • Renal Disease • Transplantation

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future. (PubMed, Transpl Int) - "Future directions for the use of belatacept need further exploration, including its role in rescuing poor renal function, its combination with low-dose CNIs, mTOR inhibitors, or tocilizumab, and its application in desensitization protocols. By potentially striking a balance between efficacy and safety, belatacept may redefine the future landscape of transplant immunosuppression."

Journal • Review • Infectious Disease • Transplant Rejection • Transplantation

Efficacy and Safety of Belatacept in Heart Transplant Recipients. (PubMed, J Heart Lung Transplant) - "BTC may safely be used as an adjunct immunosuppressive agent in HT recipients with renal dysfunction or elevated immunological risk. A BTC-based regimen is associated with improved renal function compared to a standard regimen based on calcineurin inhibitors."

Journal • Infectious Disease • Nephrology • Renal Disease • Transplantation

EPIMAC-BELA: Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients (clinicaltrials.gov) - P=N/A | N=15 | Recruiting | Sponsor: University Hospital, Tours | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Transplantation

Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study. (PubMed, J Clin Med) - "Background/Objectives: Generally, induction therapy includes basiliximab (BAS) or anti-thymocyte globulin (THY)... Specific topics related to the safety profiles of alemtuzumab, BAS, belatacept, and THY were analyzed...However, a causal relationship between the reported adverse reactions and drug efficacy cannot be established based on the present results. Further real-world evidence studies will enhance our understanding of the safety and efficacy of these drugs in transplant patients."

Adverse events • Journal • Immunology • Infectious Disease • Transplant Rejection • Transplantation

Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review. (PubMed, Viruses) - "The viremia showed an incomplete response to first-line antiviral therapy with valganciclovir, and the use of the novel antiviral agent maribavir also failed to achieve long-lasting viremic clearance. This case and literature review underscores the need for clinicians to remain vigilant for atypical CMV infections in renal transplant recipients treated with belatacept. If the complete clearance of viremia cannot be achieved despite the use of different antiviral agents, consideration should be given to modifying immunosuppressive therapy."

Journal • Review • Acute Kidney Injury • Cytomegalovirus Infection • Infectious Disease • Nephrology • Transplantation

ADVANTage: Advancing Transplantation Outcomes in Children (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Nov 2028 ➔ Jun 2028 | Trial primary completion date: Nov 2028 ➔ Jun 2028

Trial completion date • Trial primary completion date • Transplantation

Reply to "Real-world registry evidence beware: Old-world risk analysis may not be applicable to new world belatacept utilization". (PubMed, Am J Transplant) - No abstract available

Journal • Real-world evidence

Belatacept and Molecular Biomarkers: The Role of Molecular Biomarkers in Immunosuppression Management at UCLA - Wednesday, May 14, 2025, 7:00 pm.

Biomarker • Live event

Recurrent Pulmonary Alveolar Proteinosis With Negative Pathology After Bilateral Lung Transplant (ATS 2025) - "Prior to transplant, therapies including whole lung lavage and nebulized Sargramostim were trialed. Post transplant, belatacept, tacrolimus, mycophenolate, and prednisone were used for immunosuppression...Thus, clinicians should maintain a high suspicion for recurrent disease in patients with persistently positive GM-CSF autoantibodies. This case highlights the importance of early recognition and treatment for recurrent autoimmune PAP despite biopsy results after bilateral lung transplant."

Bronchiectasis • Cardiovascular • Diabetes • Fibrosis • Immunology • Infectious Disease • Metabolic Disorders • Obstructive Sleep Apnea • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sleep Disorder • Transplantation • Type 2 Diabetes Mellitus • CSF2

Belatacept as an Alternative Immunosuppressant Agent for Bone Marrow Sparing in Pulmonary Fibrosis Lung Transplant Recipients With Short Telomeres (ATS 2025) - "Patients with STL are prone to develop significant cytopenias and poor tolerance to cell cycle inhibitors, specifically Mycophenolate mofetil (MMF), post-transplant...63% (5/8) were successfully transitioned to Everolimus with median time of Belatecept use being 8 months, while 38% continued Belatacept as part of there IS regimens, along with a calcineurin inhibitor and steroid... The use of Belatacept post-lung transplant may be a well-tolerated alternative to a cell cycle inhibitor in STLPF-LTRs who develop, or at risk to develop post-transplant cytopenias."

Clinical • Hematological Disorders • Hematological Malignancies • Immunology • Myelodysplastic Syndrome • Oncology • Pulmonary Disease • Respiratory Diseases • Transplantation • RTEL1 • TERT • TINF2

Impact of Tacrolimus-to-Belatacept Conversion on Donor-Specific Antibodies in Kidney Transplant Recipients With Renal Function Decline: A Study of a French Cohort (EFI 2025) - "There were 5 (1.8%) biopsy proven acute rejection (BPAR) episodes over the first-year post-conversion. To conclude, late Tac-to-Bela conversion significantly reduce DSAs MFI and was associated with a low incidence of BPAR but the number of DSA was not modified by this conversion."

Clinical • Transplant Rejection • Transplantation

A population-based analysis of immunosuppression therapy after organ transplantation. (PubMed, BMC Health Serv Res) - "This population-based analysis of immunosuppressive therapy after organ transplantation in Germany found an increase in the use of generic immunosuppressive drugs between 2017 and 2021, although the increase was lower than expected."

Journal • Solid Organ Transplantation • Transplantation

Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes. (PubMed, Transplant Proc) - "Patient and graft survival and 30-day readmission after CHF hospital discharge did not differ significantly between belatacept conversion and CNI continuation. The incidence of rejection was higher in the belatacept conversion group, suggesting a need for closer follow-up of patients on belatacept therapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Transplantation

Donor-specific Mesenchymal Stem Cell Infusion in Human and Non-human Primate Kidney Transplantation. (PubMed, Am J Transplant) - P1 | "We report the results of two independent, concurrently performed studies evaluating the safety and efficacy of donor-derived mesenchymal stromal cell (MSC) infusions in inducing immune-tolerance in nonhuman primate (NHP) and human kidney transplant recipients treated with depletional induction and belatacept/sirolimus maintenance...In humans, six patients enrolled in ITN062ST underwent transplantation with alemtuzumab induction; four received 12 monthly donor-MSC infusions followed by immunosuppression withdrawal (ISW) if eligible...Trial Registration. ClinicalTrials.gov - NCT03504241."

Journal • Transplantation